December 21, 2004

Flamel moves hepatitis product into phase I/II

By PBR Staff Writer

The hepatitis and hepatitis C product has been developed using Flamel’s Medusa technology, which is designed to deliver controlled-release formulations of therapeutic proteins. The phase I/II study is